Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-07-31
2000-03-21
Fan, Jane
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549222, A61K 31365, C07D30902
Patent
active
060403357
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to novel 2-pyranone derivatives and pharmacologically acceptable salts thereof, as well as therapeutics for thrombocytopenia containing them as an effective ingredient. The invention also relates to intermediates for their synthesis and processes for producing them.
BACKGROUND ART
Thrombocytopenia is a disease that accompanies immunological disorders or bone marrow damaging metastatic tumors, tuberculosis, leukemia, etc. Alternatively, it is caused by other factors such as the use of chemotherapeutics or radiation therapy. Thrombocytopenia is a serious disease which, when aggravated, causes bleeding in various parts of the body, occasionally leading to death.
Symptomatic therapy by platelet transfusion is currently considered to be the sole reliable method that can treat thrombocytopenia and it is desired to develop therapeutics that can increase platelets per se.
In recent years, reports have been made that show the platelet increasing action of cytokines such as interleukin-6, interleukin-11 and leukemia inhibitory factor (LIF) (Ishibashi et al., Blood, 74:1241-1244, 1989; Asano et al., Blood, 75:1602-1605, 1990; Zenji Okada et al., KETUEKI SHUYOKA, 22:23-31, 1991). However, the production of these cytokines is regulated and controlled by various cells within the body and if they are externally administered to the body, the balance in regulation is upset, eventually causing serious side effects such as damage to the liver.
It has also been suggested recently that a protein called "thrombopoietin (TPO)" is a factor that increases megakaryocytes and platelets (see, for example, Sauvage et al., Nature, 369:533-538, 1994), however, clinical effects of this protein have not yet been verified.
Derivatives such as muramyl dipeptide are known as low-molecular weight compounds that increase the platelet count (Nakajima et al., Arzneim.-Forsch./Drug Res. 41:60-65, 1989). It is postulated that these derivatives increase platelets by activating monocytes and macrophages so as to produce interleukin-6. However, it has also been reported that the administration of derivatives such as muramyl dipeptide also triggers other physiological activities based on the activation of macrophages, thereby causing fever and other side effects (NIHON IGAKU HOSHASEN GAKKAISHI, 48(4):514, 1988).
The compounds structurally similar to the compounds of the invention are taught in Japanese Patent Public Disclosure Nos. 304893/1989 and 186/1990, as well as The Journal of Antibiotics, 42:1331-1343, 1989; they are 2-pyranone derivatives obtained as the metabolites of actinomyces of the genus Streptomyces and these compounds have been reported to have an antimicrobial action against plant pathogenic fungi, as well as cytotoxicity to leukemic cells.
In addition, Japanese Patent Public Disclosure Nos. 213758/1993 and 2886/1995 teach that 2-pyranone derivatives are compounds exhibiting a platelet increasing action in mouse. However, these compounds are not necessarily satisfactory in terms of safety.
An object of the invention is to overcome the aforementioned defects of the prior art by providing compounds that are safe and which have an action for increasing platelets per se.
DISCLOSURE OF INVENTION
The present inventors conducted intensive studies on various compounds with a view to solving the aforementioned problems and found novel 2-pyranone derivatives that had a platelet increasing action in mouse and which yet had low toxicity. The present invention has been accomplished on the basis of this finding.
Thus, the present invention provides compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: ##STR2## (where R is a group --NHCHR.sub.1 R.sub.2, --N(CHR.sub.1 R.sub.2).sub.2, --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.3, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6 (where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6, which may be the sam
REFERENCES:
patent: 4235913 (1980-11-01), Johnson et al.
patent: 4725602 (1988-02-01), Carson
patent: 5334587 (1994-08-01), Kohama et al.
patent: 5409912 (1995-04-01), Sugimura et al.
CA 110:29472, Furuhama et al., 1994.
Ishibashi et al., "Interleukin-6 is A Potent Thrombopoietic Factor In Vivo In Mice", Blood, vol. 74, No. 4, 1989, pp 1241-1244.
Asano et al., "In Vivo Effects of Recombinant Human Interleukin-6 in Primates: Stimulated Production of Platelets", Blood, vol. 75, No. 8, 1990, pp 1602-1605.
Okada et al., "In Vivo Anti-Tumor Effect By The Transfection With IL-6 Gene", Ketsueki Shuyoka, 1991, pp. 22:23-31.
Sauvage et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis y The c-Mpl Ligand", Nature, vol. 369, 1994, pp 533-538.
Nakjima et al., "Stimulatory Effect of Romurtide On Hematopoiesis in Monkeys", Arzneim-Forsch/Drug Res., vol. 41, 1991, pp 60-65.
Okawa et al., "Restorative Effect of MDP-Lys (L18) on Leukopenia of Cancer Patient Treated With Radiotherapy",Nihon Igaku Hoshasen Gakkaishi, 1988 48(4) pp 514-523.
Ozasa et al., "Novel Antitumor Antibiotic Phospholine", The Journal of Antibiotics, vol. 42, No. 9, 1989, pp 1331-1343.
Takano et al., "Seimitsu Yukigosei", Nankodo, 1983.
Fushimi et al., "Studies On New Phosphate Ester Antifungal Antibiotics Phoslactomycins", The Journal of Antibiotics, vol. 42, No. 7, 1989, pp 1019-1036.
Abstracts of the 17.sup.th Annual Meeting of the Pesticide Science Society of Japan, 1992, p. 39.
Shibata et al., "Preparation of Leustroducsin H and the Structure-Activity Relationship of Its Derivatives", The Journal of Antibiotics, vol. 48, No. 12, 1995, pp 1518-1520.
Shibata et al., "Absolute Configuration of Leustroducsins", Tetrahedron, vol. 51, No. 44, 1995, pp 11999-12012.
Haruyama Munetada
Hashino Junko
Iwasawa Norio
Kitajima Yasuo
Miura Kenju
Fan Jane
Suntory Limited
LandOfFree
Therapeutics for thrombocytopenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutics for thrombocytopenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutics for thrombocytopenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-730782